← Leaderboards
Mary-Margaret Chren
University Of California San Francisco
$4,294,686
Attributed
$4,294,686
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $619.7K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,294,686 · 4
By mechanism
R01$2,102,628 · 2
K24$1,756,446 · 1
K02$435,612 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Sharmila Majumdar$36,277,908
- Mallory O Johnson$32,174,181
- Bonnie L Halpern-Felsher$9,950,049
- Herve Y Sroussi$2,545,259
- Christine A. Miaskowski$35,237,360
Others in their field
Top investigators on “Quality Of Life”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Gregory H Reaman · National Childhood Cancer Foundation$264,644,476
- David R. Weir · University Of Michigan At Ann Arbor$263,050,576
- Richard K. Wilson · Washington University$198,912,538
Research focus
Quality Of LifeBaseSkinResearch PersonnelCaringIncidenceSkin CarcinomaTumorRecurrenceCostLearningDermatologyAwardExcisionMohs SurgeryResourcesMalignant NeoplasmsCancer TherapySkin DisorderProgramsCohortAffectBasal Cell CarcinomaCalifornia
Grant awards (23)
The e-Itch Vital Signs: development of a new mobile outcomes measure for clinical trials in patients with chronic itch$173,672
R01 · FY2020 · AR · contact PI
The e-Itch Vital Signs: development of a new mobile outcomes measure for clinical trials in patients with chronic itch$211,272
R01 · FY2019 · AR · contact PI
The e-Itch Vital Signs: development of a new mobile outcomes measure for clinical trials in patients with chronic itch$254,852
R01 · FY2018 · AR · contact PI
Patient-Oriented Research in Skin Diseases$182,524
K24 · FY2014 · AR · contact PI
Patient-Oriented Research in Skin Diseases$182,524
K24 · FY2013 · AR · contact PI
Patient-Oriented Research in Skin Diseases$182,524
K24 · FY2012 · AR · contact PI
Patient-Oriented Research in Skin Diseases$182,524
K24 · FY2011 · AR · contact PI
Patient-Oriented Research in Skin Diseases$182,524
K24 · FY2010 · AR · contact PI
Long-Term Outcomes of Nonmelanoma Skin Cancer$329,931
R01 · FY2009 · AR · contact PI
Patient-Oriented Research in Skin Diseases$169,831
K24 · FY2009 · AR · contact PI
Long-Term Outcomes of Nonmelanoma Skin Cancer$119,970
R01 · FY2009 · AR · contact PI
Long-Term Outcomes of Nonmelanoma Skin Cancer$329,931
R01 · FY2008 · AR · contact PI
Patient-Oriented Research in Skin Diseases$169,290
K24 · FY2008 · AR · contact PI
Long-Term Outcomes of Nonmelanoma Skin Cancer$336,665
R01 · FY2007 · AR · contact PI
Patient-Oriented Research in Skin Diseases$168,794
K24 · FY2007 · AR · contact PI
Long-Term Outcomes of Nonmelanoma Skin Cancer$346,335
R01 · FY2006 · AR · contact PI
Patient-Oriented Research in Skin Diseases$168,283
K24 · FY2006 · AR · contact PI
Patient Oriented Research in Skin Diseases$167,628
K24 · FY2005 · AR
COMPREHENSIVE OUTCOME OF NONMELANOMA SKIN CANCER$36,354
K02 · FY2005 · AR
COMPREHENSIVE OUTCOME OF NONMELANOMA SKIN CANCER$101,542
K02 · FY2004 · AR
COMPREHENSIVE OUTCOME OF NONMELANOMA SKIN CANCER$101,542
K02 · FY2003 · AR
COMPREHENSIVE OUTCOME OF NONMELANOMA SKIN CANCER$101,404
K02 · FY2002 · AR
COMPREHENSIVE OUTCOME OF NONMELANOMA SKIN CANCER$94,770
K02 · FY2001 · AR